Pfizer (Rights to Novel LAMA Respiratory Compound) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Pfizer (Rights to Novel LAMA Respiratory Compound) General Information

Description

Right to develop a generic drug. The asset comprises of exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. The development of the compounds will generate combination therapies and that these products will utilize the multi-dose dry powder inhaler technology.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Other Commercial Services
Acquirer
Primary Office
  • New York, NY
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pfizer (Rights to Novel LAMA Respiratory Compound) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pfizer (Rights to Novel LAMA Respiratory Compound)‘s full profile, request access.

Request a free trial

Pfizer (Rights to Novel LAMA Respiratory Compound) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pfizer (Rights to Novel LAMA Respiratory Compound)‘s full profile, request access.

Request a free trial